Format

Send to

Choose Destination
Br J Cancer. 2015 Mar 17;112(6):1027-36. doi: 10.1038/bjc.2015.72.

Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.

Author information

1
Department of General Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
2
1] Department of General Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany [2] National Centre for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
3
National Centre for Tumor Diseases, University Hospital Heidelberg, 69120 Heidelberg, Germany.
4
1] Department of General Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany [2] General and Visceral Surgery Center, 8002 Zurich, Switzerland.
5
Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, 81377 Munich, Germany.
6
1] Department of General Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany [2] Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, 81377 Munich, Germany.

Abstract

BACKGROUND:

Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment. The aim of this study was to identify immunological parameters in patients from this trial to be used for predictive and/or prognostic purposes.

METHODS:

The following methods were used: tumour immunohistology, FACS analyses, cytokine measurement, as well as cytotoxicity and ELIspot. Immunological parameters were correlated with patients' survival using the Kaplan-Meier method.

RESULTS:

Irrespective of therapy type, high lymphocyte accumulation in tumours and frequencies of NK cells and effector (eff) CD8(+) T cells in peripheral blood of the patients were associated with patients' survival. Amount of CD3(+) and effector-memory CD8(+) blood lymphocytes, expression of CD152 and interleukin (IL)-2 serum level showed a predictive value for chemoradioimmunotherapy. Tumoural accumulation of CD3(+) and CD8(+) cells was predictive for outcome of chemotherapy alone. Besides, we identified the frequencies of CD3(+) lymphocytes, effCD8(+) T cells and NK cells in the peripheral blood of the patients, and IL-10 amount in serum, to be predictive values for 5FU-based chemotherapy.

CONCLUSIONS:

Immunological parameters, identified in this trial as possible markers, may be of interest in personalized medicine towards the improvement of the treatment and prognosis of pancreatic carcinoma patients.

PMID:
25742476
PMCID:
PMC4366903
DOI:
10.1038/bjc.2015.72
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center